Takasaki Shinya, Kikuchi Masafumi, Kawasaki Yoshihide, Ito Akihiro, Arai Yoichi, Yamaguchi Hiroaki, Mano Nariyasu
Dept. of Pharmaceutical Sciences, Tohoku University Hospital.
Gan To Kagaku Ryoho. 2017 Jan;44(1):87-89.
We report the case of a patient who had renal cell carcinoma with high everolimus blood concentrations and hyperglycemia due to everolimus-induced hepatic dysfunction. A 74-year-old man who underwent right nephrectomy for renal cell carcinoma was administered everolimus for multiple lung metastases. Everolimus caused grade 3 hepatic dysfunction and hyperglycemia; hence, high blood levels of everolimus were observed. Although the patient was re-administrated everolimus after recovering from hepatic dysfunction, hepatic function test values worsened again. Everolimus was discontinued before its blood concentration increased, and the patient was switched to axitinib treatment. Therefore, the measurement of everolimus blood level is considered useful for the management of adverse events in renal cell carcinoma.
我们报告了一例肾细胞癌患者，该患者因依维莫司引起的肝功能障碍而出现依维莫司血药浓度升高和高血糖。一名74岁男性因肾细胞癌接受了右肾切除术，术后因多发肺转移接受依维莫司治疗。依维莫司导致3级肝功能障碍和高血糖；因此，观察到依维莫司血药水平升高。尽管患者肝功能障碍恢复后再次接受依维莫司治疗，但肝功能检查值再次恶化。在依维莫司血药浓度升高之前停药，并将患者改用阿昔替尼治疗。因此，依维莫司血药水平的测定被认为对肾细胞癌不良事件的管理有用。
